X

Trial Profile

An Early Phase 2 Study of KW-6356 in Subject with Early Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sipagladenant (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors Kyowa Hakko Kirin; Kyowa Kirin

Most Recent Events

01 Dec 2023 Results investigating the efficacy and safety of once-daily KW-6356, published in the Parkinsonism and Related Disorders
20 Aug 2018 According to a Kyowa Hakko Kirin media release, results from this study were presented at the 23rd World Congress on Parkinsons Disease and Related Disorders (IAPRD).
20 Aug 2018 Results presented in a Kyowa Hakko Kirin media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com